| 1AXC | A:1-126; A:127-255; C:1-126; C:127-255; E:1-126; E:127-255 | HUMAN PCNA |
| 1U76 | A:1-126; A:127-255; C:1-126; C:127-255; E:1-126; E:127-255 | CRYSTAL STRUCTURE OF HPCNA BOUND TO RESIDUES 452-466 OF THE DNA POLYMERASE-DELTA-P66 SUBUNIT |
| 1U7B | A:1-126; A:127-255 | CRYSTAL STRUCTURE OF HPCNA BOUND TO RESIDUES 331-350 OF THE FLAP ENDONUCLEASE-1 (FEN1) |
| 1UL1 | A:1-126; A:127-259; B:1-126; B:127-258; C:1-126; C:127-255 | CRYSTAL STRUCTURE OF THE HUMAN FEN1-PCNA COMPLEX |
| 1VYJ | A:1-126; A:127-257; C:1-126; C:127-257; E:1-126; E:127-257; G:1-126; G:127-260; I:1-126; I:127-257; K:1-126; K:127-257 | STRUCTURAL AND BIOCHEMICAL STUDIES OF HUMAN PCNA COMPLEXES PROVIDE THE BASIS FOR ASSOCIATION WITH CDK/CYCLIN AND RATIONALE FOR INHIBITOR DESIGN |
| 1VYM | A:1-126; A:127-256; B:1-126; B:127-256; C:1-126; C:127-256 | NATIVE HUMAN PCNA |
| 3TBL | A:1-126; A:127-256; B:1-126; B:127-256; C:1-126; C:127-258 | STRUCTURE OF MONO-UBIQUITINATED PCNA: IMPLICATIONS FOR DNA POLYMERASE SWITCHING AND OKAZAKI FRAGMENT MATURATION |
| 3VKX | A:1-126; A:127-255 | STRUCTURE OF PCNA |
| 3WGW | A:1-126; A:127-255; B:1-126; B:127-255 | STRUCTURE OF PCNA BOUND TO A SMALL MOLECULE INHIBITOR |
)
)